The momentum behind psychedelic policy reform has surged over the past five years—especially within state legislatures. With over 220 bills introduced across 38 states and D.C. since 2020, the field is evolving rapidly. But sustained progress requires a clearer understanding of what’s working—and what’s not.
Sam Chapman
In 2025 it will be 20 years since the Centre for Psychedelic Research began its study of psychedelic drugs in humans, first at Bristol University and then since 2008 at Imperial College London. What started out as an imaging study of the brain mechanisms of psilocybin in collaboration with Robin Carhart-Harris and Amanda Feilding has turned into a life changing body of research that has encompassed many hundreds of colleagues: doctors psychologists and neuroscientists.
David Nutt
State programs' equity, adverse event management, community tensions, integration with mental health system, microdosing, and indigenous community respect are key topics discussed in the video.
Rebecca Martinez, Jonathan Treem, Tracey Tee
Visionaries in Colorado and Oregon are shaping new psychedelic eco-systems by teaching, educating, and building businesses and nonprofits. Dreams are becoming reality in these emerging landscapes.
Jamie Beachy, Steve Elfrink, Martha Hammel, Nate Howard, Meaghan Len Richmond, Barine Majewska
Leaders of Oregon and Colorado campaigns discuss the historic creation of state frameworks for psychedelic healing, detailing the journey, current status, and future directions. Total words: 26
Kevin Matthews, Joshua Kappel
Psychedelic retreat centers are operating worldwide, with Oregon and Colorado preparing to regulate similar centers. These venues offer access to psychedelic experiences outside clinical settings, raising questions about their differences
Alexandra Pallas, Melissa Stangl, Ann “Annie Oak” Harrison
Psychedelic businesses have rapidly emerged on American and Canadian exchanges, creating a multibillion dollar market. Industry insiders discuss challenges and predictions for psychedelic public companies.
Patrick Trucchio, Florian Brand, George Tziras, Tim Chang
Panel on regulatory obstacles in psychedelic therapy research: Leaders from the industry discuss challenges with policymakers and predict future developments in the field.
Tadeusz Hawrot, Natasia Poinsatte, Nicole Howell
Indigenous communities are key to the emerging psychedelic industry but often see little benefit. How can companies ensure their inclusion and fair share in the growing market? Join the conversation.
Jeeshan Chowdhury, David Heldreth, Julia Mande
Dr. Smith and Dr. Jones analyze the economic impact of drug pricing and care costs on the psychedelic market at PS2023.
© 1986 – 2025 Multidisciplinary Association for Psychedelic Studies. All Rights Reserved.
3141 Stevens Creek Blvd #40563, San Jose, CA 95117.
Mailing: MAPS P.O. Box 103004 Pasadena, CA 91189-3004.